What Is Cosentyx and How Does It Target IL-17?
Cosentyx (secukinumab) is a monoclonal antibody that fully blocks IL-17A, a key cytokine driving inflammation in autoimmune diseases like psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Approved by the FDA in 2015, it leads the IL-17 inhibitor class in sales, generating over $5 billion annually due to its broad indications and strong efficacy data.[1]
How Does Cosentyx Stack Up Against Ixifi (Ixekizumab)?
Ixifi (ixekizumab, Taltz) also selectively inhibits IL-17A and matches Cosentyx in head-to-head trials for plaque psoriasis. The IXORA-R study showed ixekizumab achieving 90% skin clearance (PASI 90) in 76% of patients at week 12, versus 67% for Cosentyx, with faster onset (week 2 superiority).[2] For psoriatic arthritis, both show similar ACR20 responses around 60-70% at week 24, but ixekizumab edges out in skin outcomes. Ixekizumab has stronger data in enthesitis but carries a higher candidiasis risk (7% vs. 3% for Cosentyx).[3] Cosentyx wins on longer-term axial spondyloarthritis data.
What About Bimzelx (Bimekizumab)—The IL-17A and IL-17F Blocker?
Bimekizumab (Bimzelx) dual-inhibits IL-17A and IL-17F, potentially offering deeper inflammation control. In psoriasis trials (BE VIVID/BE READY), it hit PASI 90 in 85-91% of patients at week 16, beating Cosentyx's 74-78%.[4] For psoriatic arthritis (BE OPTIMAL), bimekizumab achieved ACR50 in 51% versus 37% for Cosentyx at week 16.[5] It excels in scalp/nail psoriasis but has higher oral candidiasis rates (15-20% vs. <5% for Cosentyx). Approved later (2021 in Europe, 2023 in US), it trails in market share but challenges Cosentyx head-on.
Key Efficacy Differences Across Psoriasis, PsA, and Axial SpA
| Indication | Cosentyx PASI 90/ACR50 (Week 12-16) | Ixekizumab | Bimekizumab |
|------------|-------------------------------------|------------|-------------|
| Plaque Psoriasis | 70-80% PASI 90 [2] | 75-85% (faster) [2] | 85-91% (superior) [4] |
| Psoriatic Arthritis | 40-50% ACR50 [3] | 45-55% [3] | 50-60% [5] |
| Axial Spondyloarthritis | ASAS40 ~60% at week 16 [6] | ~60% [6] | Limited data; not yet approved |
Cosentyx holds an edge in pediatric psoriasis approval and axial SpA experience; others lag there.
Safety Profile: Common Risks and Why They Matter
All share upper respiratory infections (10-15%) and candidiasis risks from IL-17 blockade, which impairs fungal defense. Cosentyx has the lowest severe infection rate (2-3%) and fewest IBD flares (0.4%), versus 1-2% for ixekizumab and bimekizumab.[7] Bimekizumab's dual blockade raises yeast infection concerns most. No major malignancy signals across class, but long-term data favors Cosentyx (9+ years).[1]
Dosing, Pricing, and Administration Compared
- Cosentyx: 300mg monthly subQ after loading; ~$6,000/month list price.
- Ixekizumab: 160mg loading, then 80mg every 4 weeks; similar pricing (~$5,800/month).
- Bimekizumab: 320mg every 4 weeks (no loading after first doses); ~$6,200/month, but every-8-weeks maintenance option.
Patient assistance cuts net costs; Cosentyx offers broadest insurance coverage.[8] All are self-injectable pens.
Which Doctors Pick for Patients and Why?
Rheumatologists favor Cosentyx for axial SpA and safety track record; dermatologists lean ixekizumab for rapid psoriasis clearance or bimekizumab for tough cases. Guidelines (AAD/NPF) list all as first-line biologics post-failure of TNF inhibitors, with choice based on comorbidities (e.g., avoid IL-17 in active IBD).[9] Real-world retention: Cosentyx ~70% at 12 months, similar for rivals.[10]
Sources
[1]: DrugPatentWatch.com - Cosentyx Patents
[2]: Reich et al., NEJM 2017 (IXORA-R)
[3]: Mease et al., Lancet 2018 (SPIRIT-P1)
[4]: Gordon et al., NEJM 2021 (BE VIVID)
[5]: McInnes et al., Lancet 2023 (BE OPTIMAL)
[6]: Baraliakos et al., Rheumatology 2020
[7]: Safety meta-analysis, Blauvelt et al., J Am Acad Dermatol 2022
[8]: GoodRx pricing data, 2024
[9]: AAD/NPF Guidelines 2021
[10]: SWITCH study, J Eur Acad Dermatol Venereol 2023